Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
96 enrolled
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
Phase 1 Unknown
11 enrolled
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Phase 1/2 Unknown
330 enrolled
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
260 enrolled
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma
Phase 1 Unknown
85 enrolled
Phase 1 First-in-human Study of JS014
Phase 1 Unknown
60 enrolled
HLX301
Phase 1/2 Unknown
30 enrolled
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Phase 1/2 Unknown
130 enrolled
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Phase 1/2 Unknown
80 enrolled
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Phase 1/2 Unknown
40 enrolled
A Study of TQ-B3525 on Tolerance and Pharmacokinetics
Phase 1 Unknown
60 enrolled
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
Phase 1/2 Unknown
92 enrolled
GEN602
Phase 1 Unknown
127 enrolled
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Phase 1/2 Unknown
50 enrolled
RESTORE
Phase NA Unknown
352 enrolled
A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
Phase 1/2 Unknown
72 enrolled
A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
Phase 2 Unknown
40 enrolled
A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas
Phase 1 Unknown
172 enrolled
Study of F527 in Patients With Relapsed or Refractory Lymphoma
Phase 1 Unknown
82 enrolled
A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects
Phase 1 Unknown
28 enrolled
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Phase 1/2 Unknown
68 enrolled
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Phase 1 Unknown
87 enrolled
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
Phase 3 Unknown
100 enrolled
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
Phase 2/3 Unknown
60 enrolled
GB226
Phase 1 Unknown
72 enrolled
A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas
Phase 1/2 Unknown
268 enrolled
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
Phase 1 Unknown
192 enrolled
Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Phase 1 Unknown
100 enrolled
Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
Phase 1 Unknown
20 enrolled
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children
Phase NA Unknown
30 enrolled
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
Phase 1 Unknown
50 enrolled
Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies
Phase NA Unknown
139 enrolled
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
Phase 2 Unknown
40 enrolled
Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Phase 1/2 Unknown
100 enrolled
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Phase 1/2 Unknown
73 enrolled
Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
206 enrolled
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Phase 1/2 Unknown
50 enrolled
CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma
Phase NA Unknown
6 enrolled
Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL
Phase 1 Unknown
48 enrolled
CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Phase 1 Unknown
30 enrolled
EECBL
Phase NA Unknown
24 enrolled
NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy
Phase 2 Unknown
12 enrolled
Phase I Study of Mitoxantrone Hydrochloride Liposome Injection
Phase 1 Unknown
30 enrolled
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Phase 1/2 Unknown
25 enrolled
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
Unknown
200 enrolled
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
Phase 1 Unknown
20 enrolled
Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma
Phase 2 Unknown
22 enrolled